牛牛AI助手已提取核心信息
On February 2, 2024, AbbVie Inc. reported its financial results for the fourth quarter and the full year that ended on December 31, 2023. The company experienced a decrease in full-year diluted EPS by 59.0% to $2.72 on a GAAP basis and a 19.3% decrease in adjusted diluted EPS to $11.11. Full-year net revenues declined by 6.4% to $54.318 billion, with a notable decrease in global net revenues from the immunology portfolio due to Humira biosimilar competition. However, the neuroscience portfolio saw an increase of 18.2% in global net revenues. The fourth-quarter diluted EPS also decreased by 66.7% to $0.46 on a GAAP basis and by 22.5% to $2.79 in adjusted diluted EPS. AbbVie also announced definitive agreements to acquire ImmunoGen and Cerevel Therapeutics, aiming to strengthen its oncology and neuroscience portfolios. The company provided an adjusted diluted EPS guidance range of $11.05 to $11.25 for 2024, which includes a dilutive impact from the aforementioned acquisitions. AbbVie reaffirmed its expectation for a high single-digit compound annual revenue growth rate through 2029 and raised its combined sales outlook for Skyrizi and Rinvoq to more than $27 billion by 2027.
On February 2, 2024, AbbVie Inc. reported its financial results for the fourth quarter and the full year that ended on December 31, 2023. The company experienced a decrease in full-year diluted EPS by 59.0% to $2.72 on a GAAP basis and a 19.3% decrease in adjusted diluted EPS to $11.11. Full-year net revenues declined by 6.4% to $54.318 billion, with a notable decrease in global net revenues from the immunology portfolio due to Humira biosimilar competition. However, the neuroscience portfolio saw an increase of 18.2% in global net revenues. The fourth-quarter diluted EPS also decreased by 66.7% to $0.46 on a GAAP basis and by 22.5% to $2.79 in adjusted diluted EPS. AbbVie also announced definitive agreements to acquire ImmunoGen and Cerevel Therapeutics, aiming to strengthen its oncology and neuroscience portfolios. The company provided an adjusted diluted EPS guidance range of $11.05 to $11.25 for 2024, which includes a dilutive impact from the aforementioned acquisitions. AbbVie reaffirmed its expectation for a high single-digit compound annual revenue growth rate through 2029 and raised its combined sales outlook for Skyrizi and Rinvoq to more than $27 billion by 2027.
2024年2月2日，艾伯维公司公布了截至2023年12月31日的第四季度和全年财务业绩。按公认会计原则计算，该公司的全年摊薄每股收益下降了59.0％，至2.72美元，调整后的摊薄每股收益下降了19.3％，至11.11美元。全年净收入下降6.4％，至543.18亿美元，由于Humira生物仿制药的竞争，免疫学投资组合的全球净收入显著下降。但是，神经科学投资组合的全球净收入增长了18.2％。按公认会计原则计算，第四季度摊薄后每股收益也下降了66.7％，至0.46美元，调整后的摊薄每股收益下降了22.5％，至2.79美元。艾伯维还宣布了收购ImmunoGen和Cerevel Therapeutics...展开全部
2024年2月2日，艾伯维公司公布了截至2023年12月31日的第四季度和全年财务业绩。按公认会计原则计算，该公司的全年摊薄每股收益下降了59.0％，至2.72美元，调整后的摊薄每股收益下降了19.3％，至11.11美元。全年净收入下降6.4％，至543.18亿美元，由于Humira生物仿制药的竞争，免疫学投资组合的全球净收入显著下降。但是，神经科学投资组合的全球净收入增长了18.2％。按公认会计原则计算，第四季度摊薄后每股收益也下降了66.7％，至0.46美元，调整后的摊薄每股收益下降了22.5％，至2.79美元。艾伯维还宣布了收购ImmunoGen和Cerevel Therapeutics的最终协议，旨在加强其肿瘤学和神经科学产品组合。该公司提供的2024年调整后的摊薄每股收益指导区间为11.05美元至11.25美元，其中包括上述收购的摊薄影响。艾伯维重申了其对到2029年实现较高的个位数复合年收入增长率的预期，并将Skyrizi和Rinvoq的合并销售前景提高到2027年超过270亿美元。
有用
没用